Eversept Partners, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001697013

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q4 2023 · 57 positions · Total reported value $1.14B · Top-10 concentration 61.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.4% · 29 new · 41 cut · 27 exited

Active Share (vs S&P 500): 97.5% · vs QQQ: 99.8% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.9% · vs SPY -2.9% · Prev Value $1.87B — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2023 13F filing, Eversept Partners, LP disclosed 57 equity positions with a combined reported value of $1.14B. The filing implies a focused portfolio: its ten largest positions account for 61.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2023 were NTRA ($141.04M), GSK ($110.18M), SNDX ($73.11M). By sector, the heaviest allocations are Health Care 76.4%, Industrials 4.1%. Versus the prior quarter, allocation shifted toward Health Care (+11.4pp), Industrials (+0.5pp) and away from Other (-12.3pp).

Versus the prior quarter, Eversept Partners, LP opened 29 new positions, trimmed 41 and fully exited 27, a turnover rate of 66.4% of positions. The portfolio's overlap with the prior quarter was 74% of names.

The largest new positions opened in Q4 2023 were IMGN ($22.21M), THC ($14.15M), ZIMV ($9.70M).

Of the 27 positions fully exited versus the prior quarter, the largest were HZNP ($23.81M), AMRX ($11.16M), IBB ($8.60M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2023)

  • IMGN IMMUNOGEN INC · $22.21M
  • THC TENET HEALTHCARE CORP · $14.15M
  • ZIMV ZIMVIE INC · $9.70M
  • IMVT IMMUNOVANT INC COM · $4.79M

Fully Exited (vs previous quarter)

  • HZNP HORIZON THERAPEUTICS PUB L · prev qtr: $23.81M
  • AMRX AMNEAL PHARMACEUTICALS INC · prev qtr: $11.16M
  • IBB ISHARES TR · prev qtr: $8.60M
  • TLT ISHARES TR · prev qtr: $8.31M
  • HYG ISHARES TR · prev qtr: $6.63M
  • APLS APELLIS PHARMACEUTICALS INC · prev qtr: $4.67M
  • MRVI MARAVAI LIFESCIENCES HLDGS I · prev qtr: $4.52M
  • AMN AMN HEALTHCARE · prev qtr: $4.26M · history

Insider Transactions (Form 4)

Latest Eversept Partners, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Eversept Partners, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 119 US equity positions with a combined value of $1.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-108771 (status: Approved), registered 2017-01-11
  • Regulatory AUM (Form ADV): $2.65B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 99%, registered investment companies 1%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: eversept.com

Portfolio Structure

  • 119 positions · $1.91B reported value (Q2 2026)
  • Top 10 holdings = 46.1% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 8.2%
  • Average position size: $16.06M

Sector Tilt

  • Health Care 88.2%
  • Real Estate 5.6%
  • Industrials 1.3%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 29 new, 42 added, 41 reduced, 27 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 76.4%
Other 16.7%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.25M $141.04M 12.39%
12.39%
Reduce
2 2.97M $110.18M 9.68%
9.68%
Reduce
3 3.38M $73.11M 6.42%
6.42%
Add
4 351.12K $71.43M 6.28%
6.28%
Add
5 6.15M $64.25M 5.64%
5.64%
Reduce
6 150.00K $61.43M 5.40%
5.40%
Reduce
7 120.00K $57.04M 5.01%
5.01%
Reduce
8 246.23K $54.14M 4.76%
4.76%
Reduce
9 465.31K $35.90M 3.15%
3.15%
Add
10 494.92K $32.81M 2.88%
2.88%
Add
11 85.83K $32.65M 2.87%
2.87%
Add
12 114.81K $31.08M 2.73%
2.73%
Add
13 754.11K $29.91M 2.63%
2.63%
Add
14 1.91M $29.45M 2.59%
2.59%
Add
15 7.23M $22.63M 1.99%
1.99%
Add
16 748.95K $22.21M 1.95%
1.95%
New
17 183.06K $20.01M 1.76%
1.76%
Add
18 324.65K $16.42M 1.44%
1.44%
Add
19 233.84K $14.69M 1.29%
1.29%
Add
20 75.82K $14.45M 1.27%
1.27%
Reduce
21 187.26K $14.15M 1.24%
1.24%
New
22 538.07K $12.34M 1.08%
1.08%
Add
23 86.61K $12.06M 1.06%
1.06%
Reduce
24 255.99K $10.70M 0.94%
0.94%
Hold
25 80.80K $10.02M 0.88%
0.88%
Reduce
26 546.44K $9.70M 0.85%
0.85%
New
27 41.04K $9.49M 0.83%
0.83%
Reduce
28 1.53M $9.16M 0.81%
0.81%
Reduce
29 27.72K $9.13M 0.80%
0.80%
Add
30 688.93K $8.29M 0.73%
0.73%
Reduce
31 1.70M $7.34M 0.65%
0.65%
Add
32 97.20K $7.21M 0.63%
0.63%
Reduce
33 15.09K $7.12M 0.62%
0.62%
Reduce
34 3.78M $6.69M 0.59%
0.59%
Add
35 6.43M $5.87M 0.52%
0.52%
Add
36 6.10M $5.30M 0.47%
0.47%
Reduce
37 37.85K $5.26M 0.46%
0.46%
Reduce
38 1.14M $4.86M 0.43%
0.43%
Reduce
39 113.79K $4.79M 0.42%
0.42%
New
40 1.06M $4.53M 0.40%
0.40%
Add
41 15.42K $4.36M 0.38%
0.38%
Reduce
42 374.40K $4.18M 0.37%
0.37%
Reduce
43 115.73K $3.18M 0.28%
0.28%
Reduce
44 137.34K $2.99M 0.26%
0.26%
Reduce
45 125.96K $2.88M 0.25%
0.25%
Add
46 66.90K $2.86M 0.25%
0.25%
Reduce
47 12.26K $2.84M 0.25%
0.25%
Reduce
48 1.75M $2.45M 0.22%
0.22%
Reduce
49 6.12K $2.21M 0.19%
0.19%
Reduce
50 1.31M $2.13M 0.19%
0.19%
Reduce

FAQ

What did Eversept Partners, LP buy in 2023-Q4?

In its 2023-Q4 13F filing, Eversept Partners, LP reported 57 equity positions worth $1.14B in aggregate; its largest disclosed positions were NTRA ($141.04M), GSK ($110.18M), SNDX ($73.11M).

How large is Eversept Partners, LP's portfolio?

Eversept Partners, LP reported $1.14B of long equity holdings across 57 positions as of 2023-Q4. Top-10 holdings account for 61.6% of reported value.

What is Eversept Partners, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eversept-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →